LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

SMEs in Europe’s bioeconomy and agri-food landscape

10/01/2025

REPORT

Small and medium-sized companies (SMEs) represent 99% of all businesses in the EU and are one of the main drivers for EU competitiveness and innovation. In the bio-based industries, one million new jobs could be created by 2030 due to the fast-growing startup ecosystem in the biotechnology sector.

On November 19, 2024, EuropaBio's SME Platform hosted a roundtable discussion to explore the role SMEs in shaping Europe's regional and national bioeconomy, particularly in the agri-food sector. This session was part of EFIB – the European Forum for Industrial Biotechnology and the Bioeconomy. The meeting was supported and co-hosted by the Grand Est Representation to the EU.

The discussion was held as a roundtable, with 20 participants from the European Commission, Permanent Representations to the European Union, Council of Regions, EuropaBio secretariat, national associations and SMEs.

This executive report summarises their insights, with additional input from EuropaBio SME members. It highlights the challenges and contributions of SMEs to the bioeconomy, examines the policy landscape at national and regional levels, and offers reflections for future EU policymaking.

You can read the full report by downloading it below

SMEs in Europe's bioeconomy and agri-food landscape


Download
Share
Adrian Lincoln
Adrian Lincoln

Related posts

10/06/2025

EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union


Read more
10/06/2025

The EU economic and scientific future starts with the EU Biotech Act


Read more
05/06/2025

The GPL must include biotech & life science to unleash EU innovation


Read more

Important links

  • EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • The EU economic and scientific future starts with the EU Biotech Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.